Evidence map›Paper›PMID 35401550›Full record

ArticleFrontiers in immunology2022

Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities.

Michael Levraut, Cassandre Landes, Lydiane Mondot, Mikael Cohen, Saskia Bresch, Vesna Brglez, Barbara Seitz-Polski, Christine Lebrun-Frenay

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Michael LevrautURRIS-UR2CA, Centre Hospitalier Universitaire de Nice, Nice, France.
Cassandre LandesURRIS-UR2CA, Centre Hospitalier Universitaire de Nice, Nice, France.
Lydiane MondotURRIS-UR2CA, Centre Hospitalier Universitaire de Nice, Nice, France.
Mikael CohenURRIS-UR2CA, Centre Hospitalier Universitaire de Nice, Nice, France.
Saskia BreschDépartement de Neurologie, CRC SEP, Centre Hospitalier Universitaire de Nice, Nice, France.
Vesna BrglezImmunoPredict-UR2CA, Centre Hospitalier Universitaire de Nice, Nice, France.
Barbara Seitz-PolskiImmunoPredict-UR2CA, Centre Hospitalier Universitaire de Nice, Nice, France.
Christine Lebrun-FrenayURRIS-UR2CA, Centre Hospitalier Universitaire de Nice, Nice, France.
Centre Hospitalier Universitaire de Nice · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Many patients are referred to multiple sclerosis (MS) tertiary centers to manage brain white matter hyperintensities (WMH). Multiple diagnoses can match in such situations, and we lack proper tools to diagnose complex cases. Objective: This study aimed to prospectively analyze and correlate with the final diagnosis, cerebrospinal fluid (CSF) interleukin (IL)-1β, soluble IL-2 receptor (CD25), IL-6, IL-10, and kappa free light chains (KFLC) concentrations in patients presenting with brain WMH. Methods: All patients over 18 years addressed to our MS tertiary center for the diagnostic workup of brain WMH were included from June 1, 2020, to June 1, 2021. Patients were separated into three groups-MS and related disorder (MSARD), other inflammatory neurological disorder (OIND), and non-inflammatory neurological disorder (NIND) groups-according to clinical presentation, MRI characteristics, and biological workup. Results: A total of 176 patients (129 women, mean age 45.8 ± 14.7 years) were included. The diagnosis was MSARD ( Discussion: Our results show that, as OCBs, KFLC biomarkers are helpful tools to rule in MSARD, whereas elevated CSF CD25 and IL-6 rule out MSARD. Interestingly, CSF IL-6 concentration could help identify neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and central nervous system (CNS) vasculitis. These results need to be confirmed within more extensive and multicentric studies. Still, they sustain that KFLC, CSF CD25, and CSF IL-6 could be reliable biomarkers in brain WMH diagnostic workup for differentiating MSARD from other brain inflammatory MS mimickers.

Indexed as

Multiple SclerosisWhite MatterAdultBiomarkersBrainFemaleHumansImmunoglobulin kappa-ChainsInterleukin-10Interleukin-1betaInterleukin-2 Receptor alpha SubunitInterleukin-6MaleMiddle AgedBiomarkersIL10 protein, humanIL1B protein, humanIL2RA protein, humanIL6 protein, humanImmunoglobulin kappa-ChainsInterleukin-10Interleukin-1betaInterleukin-2 Receptor alpha SubunitInterleukin-6biomarkerIL-6kappa free light chainsmultiple sclerosissIL-2Rwhite matter hyperintensities

Identifiers

PMID35401550
PMCPMC8990749
OpenAlexW4226077761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.